Management of Atopic Dermatitis: The Role of Tacrolimus

Badar Uddin Umar 1, Sayeeda Rahman 2, Siddhartha Dutta 3, Tariqul Islam 4, Nadia Nusrat 5, Kona Chowdhury 6, Wan Farizatul Shima Binti Wan Ahmad Fukuradzi 7, Mainul Haque 8

1. Medical Education, Oxford College of Arts, Business and Technology, Toronto, CAN 2. School of Medicine, American University of Integrative Sciences, Bridgetown, BRB 3. Pharmacology, All India Institute of Medical Sciences, Raikut, IND 4. Community Medicine, Gonoshasthaya Samaj Vittik Medical College, Dhaka, BGD 5. Pediatrics, Delta Medical College & Hospital, Dhaka, BGD 6. Pediatrics, Gonoshasthaya Samaj Vittik Medical College, Dhaka, BGD 7. Community Medicine, Faculty of Medicine and Defence Health, Universiti Pertahanan Nasional Malaysia (National Defence University of Malaysia), Kuala Lumpur, MYS 8. Pharmacology and Therapeutics, National Defence University of Malaysia, Kuala Lumpur, MYS

Corresponding author: Mainul Haque, runurono@gmail.com

Abstract

Atopic dermatitis (AD) is a long-lasting inflammatory dermatological condition characterized by itchy, eczematous, sparsely tiny blisters that hold a clear watery substance. Additionally, the diseased skin can suppurate, occasionally with weeping with thickening of the affected skin. This is considered one of the top skin disorders involving both children and adult populations globally. The principal therapeutic intervention for AD is long-standing topical glucocorticoids, which have been used for several decades. Corticosteroid therapy brings several adverse drug effects (ADRs), including irreversible skin atrophy. Tacrolimus belongs to the class of calcineurin inhibitors, which is a type of immunomodulator possessing promising efficacy in treating AD. Topical tacrolimus is an effective and safe non-corticosteroid substitute treatment for AD. We reviewed the available literature to compare and institute the safety, efficacy, and effectiveness of tacrolimus when equated to corticosteroid therapy in managing AD.

Introduction And Background

Tacrolimus is a very potent anti-T-lymphocyte, macrolide, and immunosuppressant medicine produced from the fungus Streptomyces tsukubaensis; it was discovered in 1984 [1-3]. It has been reported that the therapeutic interventions for atopic dermatitis (AD) have vastly changed after the advent of tacrolimus [4]. The topical application of tacrolimus at a concentration of 0.03% to 0.1% has been reported to possess effectiveness therapeutically among pediatric (middle childhood [2-6 years] and school aged [7-15 years] children) and adult patients [4-6]. A lower concentration (0.03%) in the pediatric age cluster is recommended and is contraindicated in the usage below two years of age [7].

Diverse role of tacrolimus as an immunomodulator in transplant and dermatology

The concept of substituting poorly or not functioning vital body parts or tissues with physiologically healthy (homologous) ones is an old concept [8,9]. Nevertheless, in 1954, the first effective and efficient human renal transplant was achieved [9]. In the last 70 years, there has been a massive improvement in transplant-related surgical methods, instruments, and organ conservation [9-12]. Comprehensive pathophysiological knowledge regarding immunologic barriers to transplantation has improved immensely. [12,13] The progress of novel immunosuppressive agents with higher potent effects was the principal driving force for the human organ transplantation routine [8,14,15]. The current success of transplantation and prolonging human life is often notified because of tacrolimus (FK506) [9,16-19]. Some multicentered studies demonstrated therapeutic safety and efficiency of systemic and topical use of tacrolimus in common inflammatory skin diseases such as psoriasis and AD, with only a few local side effects [20].

Atopic dermatitis

Brief Overview Atopic Dermatitis

AD is a long-lasting, reverting, exceedingly pruritic inflammatory condition, and one of the top dermatological disorders [21-23]. AD is considered a specific form of eczema causing intense itching and considerable sleep disorders and often promotes social stigma and increases emotional and psychological stress [24-28]. This dermatological disease significantly increases morbidity and destructively disturbs the patient’s and family’s quality of life [29-33]. To date, the pathology of the disease remains obscure.
Nevertheless, it involves an abnormally functioning immune system, genetic predisposition, epidermal gene metamorphosis, and atmospheric aspects that instigate the disruption of the epidermal physiology and promote the development of AD [34-39], and it is frequently found challenging to relieve these patients [40]. The management of this dermatological disorder is expensive among Asian communities, thereby increasing the disease burden and financial overhead both at the level of individual and society [41-43]. In the USA, the annual financial overhead cost of AD was US$5.297 billion in 2015 through conventional appraisal [45].

AD is a systemic disease [44] categorized by anomalous epidermal wall physiology [45], and it can spread over various parts of the body with multiorgan involvement [46]. The origin of epidermal wall interruption is composite and determined by multiple triggering features including structural, family inherited, environs, and immunological aspects [54,47-49]. Furthermore, epidermal and gut microbiota modification often influences AD's disease severity, length, and poor response to therapeutic intervention [50,51]. Clinically, AD can make headway from dermatological disorders to food hypersensitivities, hay fever, and later bronchial asthma, frequently recognized as the atopic march [52,53]. Additionally, multiple studies have reported that AD has the potential to develop systemic inflammatory diseases involving gastrointestinal or airway disorders. Nevertheless, these findings have not yet been verified scientifically [44,54,55].

Glucocorticoid in Atopic Dermatitis

Glucocorticoids directly applied to the affected part of the skin remain the backbone of AD management over the previous 60 years [56-58]. Hydrocortisone was identified as the initial steroid cast-off in AD [56-58]. Later, the world’s regulatory bodies approved 30 glucocorticoid molecules with diverse potency for treating AD [56]. It has been reported that topical glucocorticoids are recurrently irrationally prescribed and consumed [59-61]. The long-standing use of dermal glucocorticoids is associated with adverse drug reactions (ADRs) [62]. The reported ADRs are hooked on the biochemical properties of the drug, the vehicle, and at the site of medicine applied [63]. ADRs such as atrophy, striae, rosacea, perioral dermatitis, acne, and purpura are repeatedly reported. Hypertrichosis, pigmentation remodeling, retard traumatic lesion to reinvigorate process, and exasperation of dermatological infections are also low in frequency [59,60,65-65]. Therefore, it has been advised that even topical glucocorticoid administration should be carefully monitored to minimize ADRs [61,62]. Doctors and nurses should counsel the patients on applying topical high-potency steroids to maximize the benefit and minimize ADRs [65,65-68]. High-potency dermatological corticosteroids must not be used for two to four weeks [60,65,69].

Review

Tacrolimus: mode of action

Dermatological tacrolimus is a useful immunomodulator [70,71]. It attaches to specific cytoplasmic immunophilin (FKBP12), Ca2+, and calmodulin, hindering or suppressing calcineurin’s phosphatase activity. This further impairs the nuclear factor of activated T-cells (NFAT) signaling process by preventing its dephosphorylation, which cumbers upon interleukin-2 (IL-2) generation and results in diminished T-cell activation and inflammatory cytokine let out [72-74]. Topical tacrolimus reduces mononuclear cell infiltration, thereby partly bringing back hair growth and hence can be valuable in alopecia areata [20,75,76]. It is also reported that tacrolimus impedes the conglomerate of IL-2, IL-5, IL-4, tumor necrosis factor-alpha (TNF-α), and granulocyte-macrophage colony-stimulating factor (GM-CSF) [1]. Apart from these, there is also evidence that tacrolimus hinders the let-out pre-formed inflammatory molecules from mast cells and basophils present in the skin layers and minimizes the utterance of FcεRI on Langerhans cells [77,78].

Topical tacrolimus is helpful for several inflammatory skin disorders, including vitiligo, psoriasis, alopecia areata, contact allergy, lichen planus, pyoderma gangrenosum, ichthyosis linearis circumflexa, and skin grafting/transplant [4,79-81].

Advantage of tacrolimus over corticosteroids

Efficacy and Effectiveness

Various studies have demonstrated the benefits and ADRs of tacrolimus in contrast to either vehicle base or diverse potencies of dermal glucocorticoids. Several clinical studies have established tacrolimus’s relative efficacy (Table 1) and safety over corticosteroids [82-89]. There is abundant evidence suggesting the safety and efficacy of tacrolimus and other calcineurin inhibitors over long-term topical corticosteroid therapy for AD and other dermatological conditions [84,90-93]. The beneficial and advantageous effects of tacrolimus were found in pediatric and adult patients with AD (Table 1) [94].
Multiple studies observed that individuals with tolerable to grave AD showed noticeable more overall global improvement with topical tacrolimus (0.1% and 0.03%) than with the mild-to-moderate potent dermatological glucocorticoid after seven days [95-98]. Local application of tacrolimus was found to be efficacious and had low-profile ADRs, and thus is considered mainstream medication for AD patients [99]. The most common ADRs with tacrolimus were local irritations at the application site, generally resolved with continual treatment. The findings suggested that dermal tacrolimus is an effective, safe, non-corticosteroid substitute treatment for AD [82]. A study compared 0.1% topical use of tacrolimus with glucocorticoids. The tacrolimus and its' congeners significantly improved the affected body surface area (p<0.001), higher than the steroidal cluster [98]. It was assessed through a modified eczematous area and severity index (mEASI), eczematous area, and severity index (EASI). The tacrolimus cluster suffered a higher rate (P<0.001) of a smoldering commotion than the corticosteroids. However, the skin burning resolved in one week, and no infection or malignancies were reported [98]. Topical tacrolimus 0.03% has been found as more efficacious and safer than mild corticosteroids. Besides AD, tacrolimus also showed promising efficacy in other conditions, including oral lichen planus and labial discoid lupus erythematosus [100,101].

Safety

Adverse effect profiles of both long-term and short-term corticosteroids are more serious than tacrolimus [102]. The most frequent adverse effect of topical tacrolimus includes a burning sensation on the skin or irritation. However, burning skin-related adverse effects most frequently appear in the early part of the pharmacological intervention and usually exist for short periods. It has been reported that skin irritation stops within the first few days of therapy [103]. Topical tacrolimus does not cause skin atrophy, which occurs during the treatment with topical corticosteroids [104]. Tacrolimus dermatological preparation was not associated with an increased risk of cutaneous infections (bacterial and viral infections), which usually

### TABLE 1: Studies showing a comparison between tacrolimus (calcineurin inhibitors) and corticosteroids

| Authors                        | Year   | Study Type: Disease                      | Drugs Used                                      | Result/Findings                                                                 |
|--------------------------------|--------|------------------------------------------|------------------------------------------------|
| Mandelin et al. [84]           | 2010   | RCT: AD                                  | Tacrolimus ointment, Hydrocortisone acetate 1%, Hydrocortisone butyrate 0.1% | Tacrolimus was found to have superior efficacy over steroids. The AE profile of corticosteroids was a little better, not statistically significant though (40/40 vs. 34/40, respectively. |
| Axon et al. [85]               | 2021   | Umbrella review: AD                     | Topical corticosteroids, Topical calcineurin inhibitors, Vehicles/emollients | There was a higher relative risk of skin thinning with topical corticosteroids. Biochemical adrenal suppression was evident with corticosteroids. |
| Tabędź and Pawliczak R. [86]   | 2019   | Meta-analysis of RCTs: AD               | Tacrolimus (0.3%, 0.1%), Pimecrolimus (1%), Glucocorticoids | Calcineurin inhibitors were significantly more effective. Skin burning and pruritus were the common AEs. |
| Koh et al. [87]                | 2021   | Retrospective review of medical records: ocular surface inflammation in pediatric patients | Topical tacrolimus (0.02%). Topical corticosteroids | 48% of patients recovered fully before 12 months, and 56% continued 12 months of therapy. All patients who continued showed improvement with tacrolimus. AEs were more familiar with corticosteroids. |
| Ohitsu et al. [83]             | 2018   | Review: AD                              | Topical tacrolimus, Topical corticosteroids | Tacrolimus is effective and well tolerated in the long-term treatment and can improve quality of life. There is no current strong evidence of an increased malignancy in risks. Data from post-marketing surveillance show no safety concerns. |
| Nakagawa [82]                 | 2006   | Review of randomized, double-blind clinical studies: AD | Topical tacrolimus 0.1%. Topical corticosteroids | Tacrolimus is superior to mild potency corticosteroids in both efficacy and safety. Tacrolimus is safe in long-term use too. |
| Svensson et al. [94]           | 2011   | A systematic review of tacrolimus ointment compared with corticosteroids: AD | Tacrolimus 0.1% ointment. Class I, II, and II corticosteroids | Tacrolimus and topical corticosteroids are effective in AD in children and adults. |
coexist with AD [105-108]. Other cutaneous infections found due to treatment with tacrolimus include herpes simplex, varicella, and eczema herpeticum [108,109]. Many studies have warned about the potential risk of developing cancer (mainly lymphoma and skin cancer) [110-112]. However, other research revealed that the use of topical calcineurin inhibitors is not grounded on long-standing safety data and the information derived from animal studies [91,113,114]. However, studies do not reveal that tacrolimus raises the risk of lymphoma and melanoma skin cancer [92,91,110,115-119]. Long-standing safety of topical tacrolimus was observed in trials for up to four years [84]. A study on healthy volunteers demonstrated that tacrolimus causes almost no functional changes to healthy skin due to its poor permeability compared to topical corticosteroids [120].

The topical use of corticosteroids may cause skin atrophy; however, there was no reported possibility of malignancies or skin atrophy due to tacrolimus [85,97]. Tacrolimus effectively treats moderate-to-severe AD without causing atrophy due to prolonged use of topical corticosteroids [121].

Conclusions
AD is a continuing inflammatory dermal disease that negatively impacts the patient’s quality of life. It affects both children and adults. The treatment is usually long-term and often unsatisfactory on account of the ADRs and the possibility of relapse. There has been a continuous search for a safer, efficacious therapy for long-term remission. Among the available corticosteroids, calcineurin inhibitors, emollients, antihistamines, and immunosuppressants are mentioned. This review intended to explore the efficacy and safety of tacrolimus over topical steroids. It was evident from the available trials, systematic reviews, and other studies that tacrolimus is equi-efficacious to glucocorticoids in ameliorating AD symptoms. Except for skin irritation or burning sensation, the safety profile of tacrolimus is similar to that of corticosteroids. Appropriate patient education can help patients and families overcome the fear of AD therapy. Large-scale clinical trials, systematic reviews, and meta-analyses could improve comprehension knowledge regarding the safety and efficacy of tacrolimus. This can motivate drug regulatory agencies to review the drugs’ safety warnings.

Additional Information
Disclosures
Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that they are no other relationships or activities that could appear to have influenced the submitted work.

Acknowledgements
The authors have reviewed and approved the final version and have agreed to be accountable for all aspects of the work, including any accuracy or integrity issues.

References
1. Đe Tran QH, Guay E, Chartier S, Trousignant J: Tacrolimus in dermatology. J Cutan Med Surg. 2001, 5:529-35. 10.1007/s102200000022
2. Wallemacq PE, Reding R: FK506 (tacrolimus), a novel immunosuppressant in organ transplantation: clinical, biomedical, and analytical aspects. Clin Chem. 1993, 39:2219-28. 10.1093/clinchem/39.11.2219
3. Haroon N, Singh A, Bhat ZY: Tacrolimus toxicity with minimal clinical manifestations: a case report and literature review. Am J Ther. 2016, 23:e631-4. 10.1097/MJT.0000000000000219
4. Sehgal VN, Srivastava G, Dogra S: Tacrolimus in dermatology-pharmacokinetics, mechanism of action, drug interactions, dosages, and side effects: part I. Skinnmed. 2008, 7:27-30. 10.1111/j.1540-9740.2007.06485.x
5. Hanifi JM, Ling MR, Langley R, Breneman D, Rafal E: Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part I. Efficacy. J Am Acad Dermatol. 2001, 44:S28-38. 10.1067/jaad.2001.109810
6. Paller A, Eichenfield LF, Leung DY, Stewart D, Appell M: A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. J Am Acad Dermatol. 2001, 44:S47-57. 10.1067/mjd.2001.109815
7. The Electronic Medicines Compendium (EMC). Protopic 0.03% ointment . (2021). Accessed: July 25, 2022: https://www.medicines.org.uk/emc/product/1612/smpc.
8. Mao AS, Mooney DJ: Regenerative medicine: current therapies and future directions. Proc Natl Acad Sci U S A. 2015, 112:14452-9. 10.1073/pnas.150820112
9. Fung JJ: Tacrolimus and transplantation: a decade in review . Transplantation. 2004, 77:S41-3. 10.1097/01.TP.0000026792.61454.a5
10. Watson CJ, Dark IH: Organ transplantation: historical perspective and current practice . Br J Anaesth. 2012, 108 Suppl 1:29-42. 10.1093/bja/aer834
11. Yilmaz S, Akbulut S: In memoriam of Thomas Earl Starzl, the pioneer of liver transplantation . World J Transplant. 2022, 12:55-8. 10.5500/wjt.v12.i3.55
12. Giwa S, Lewis JK, Alvarez L, et al.: The promise of organ and tissue preservation to transform medicine . Nat Biotechnol. 2017, 35:530-42. 10.1038/nbt.3889
82
81
80
78
77
76
74
73
65
64
63
62
61
60
59
58
55
54
53
51
50
49
48
47
46
45
44
43
42
41
40
39
38
37
36
35
34
33
32
31
30
29
28
27
26
25
24
23
22
21
20
19
18
17
16
15
14
13
12
11
10
9
8
7
6
5
4
3
2
1

47. Czarnowicki T, Krueger JG, Gutman-Yassky E: Novel concepts of prevention and treatment of atopic dermatitis through barrier and immune manipulations with implications for the atopic march. J Allergy Clin Immunol. 2017, 159:1725-34. 10.1016/j.jaci.2017.04.004
48. Rekhrismit P, Otsaka A, Nakashima G, Kabaisha K: The etiopathogenesis of atopic dermatitis: barrier disruption, immunological derangement, and pruritus. Inflamm Regen. 2017, 37:14. 10.1186/s41232-017-0044-7
49. Fujii M: Current understanding of pathophysiological mechanisms of atopic dermatitis: interactions among skin barrier dysfunction, immune abnormalities, and pruritus. Biol Pharm Bull. 2020, 43:12-9. 10.1248/bpb.b19-00088
50. Kim JE, Kim HS: Microbiome of the skin and gut in atopic dermatitis (AD): understanding the pathophysiology and finding novel management strategies. J Clin Med. 2019, 8:444. 10.3390/jcm8040444
51. Baviera G, Leoni MC, Capra L, et al.: Microbiota in healthy skin and in atopic eczema. Biomed Res Int. 2014, 2014:436921. 10.1155/2014/436921
52. Han H, Roan F, Ziegler SF: The atopic march: current insights into skin barrier dysfunction and epithelial cell-derived cytokines. Immunol Rev. 2017, 278:116-30. 10.1111/imr.12546
53. Zheng T, Yu J, Oh MH, Zhu Z: The atopic march: progression from atopic dermatitis to allergic rhinitis and asthma. Allergy Asthma Immunol Res. 2011, 3:57-73. 10.4168/aiar.2011.3.2.67
54. Oliveira G, Torres T: More than skin deep: the systemic nature of atopic dermatitis. Eur J Dermatol. 2019, 29:250-8. 10.1684/ejd.2019.3557
55. Mocanu M, Vâjâi D, Alexa AI, Transafir L, Patrașcu AI, Hâncu MF, Gheușă-Solovâstru L: Atopic dermatitis beyond the skin. Diagnostics (Basel). 2021, 11:1555. 10.3390/diagnostics11091553
56. Atherton DJ: Topical corticosteroids in atopic dermatitis. BMJ. 2003, 327:942-3. 10.1136/bmj.327.7421.942
57. Galli E, Neri I, Ricci G, et al.: Consensus conference on clinical management of pediatric atopic dermatitis. J Pediatr. 2016, 142:26. 10.1016/j.jpeds.2016.02.029-8
58. Matthewsman J, Mansfield KE, Prieto-Alhambra D, et al.: Atopic eczema-associated fracture risk and oral corticosteroids: a population-based cohort study. J Allergy Clin Immunol Pract. 2020, 22:2576-66. 10.1016/j.jaip.2020.09.026
59. Coondoo A, Phiske M, Verma S, Lahirì K: Side-effects of topical steroids: a long overdue revisit. Indian Dermatol Online J. 2014, 5:416-25. 10.4103/2229-5178.142485
60. Gabros S, Nessel TA, Zito PM: Topical corticosteroids. StatPearls [Internet]. StatPearls Publishing, Treasure Island, FL; 2022.
61. Saraswat A: Ethical use of topical corticosteroids. Indian J Dermatol. 2014, 59:469-72. 10.4103/0019-5154.159877
62. Yasir M, Goyal A, Bansal P, et al.: Corticosteroid adverse effects. StatPearls [Internet]. StatPearls Publishing, Treasure Island, FL; 2022.
63. Stacey SK, McEleney M: Topical corticosteroids: choice and application. Am Fam Physician. 2021, 103:537-43.
64. Tan SY, Chandran NS, Choi EC: Inhibition of T helper cell differentiation by tacrolimus or sirolimus results in reduced B-cell activation: effects on T follicular helper cells. Transplant Proc. 2017, 50:2127-73. 10.1016/j.transproceed.2019.08.039
65. Price VH: Therapy of alopecia areata: on the cusp and in the future. J Investig Dermatol Symp Proc. 2005, 8:207-11. 10.1046/j.1198-7355.2005.00811.x
66. Guo H, Cheng Y, Shapiro J, McElwee K: The role of lymphocytes in the development and treatment of alopecia areata. Expert Rev Clin Immunol. 2015, 11:1553-51. 10.1586/174466XX.2015.1085306
67. Food and Drug Administration. PROTOPIC® (tacrolimus) Ointment 0.03%, Ointment 0.1% (2021). Accessed: July 25, 2022: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/050777s018lbl.pdf
68. The Electronic Medicines Compendium (EMC). Protopic 0.1% ointment. (2021). Accessed: July 25, 2022: https://www.medicines.org.uk/emc/product/1608/sumc
69. Carroll CL, Fleisher AB Jr: Tacrolimus ointment: the treatment of atopic dermatitis and other inflammatory cutaneous disease. Expert Opin Pharmacother. 2004, 5:2127-37. 10.1517/14656566.5.10.2127
70. Sebagh VN, Srivastava G, Dogra S: Tacrolimus: approved and unapproved dermatologic indications/usese-physician’s sequential literature survey: part II. Skimed. 2008, 7:73-7. 10.1111/j.1751-7125.2008.006514.x
71. Bergman J, Rico Mj: Tacrolimus clinical studies for atopic dermatitis and other conditions. Semin Cutan Med Surg. 2001, 20:250-9. 10.1053/semder.2001.29661
72. Nakagawa H: Comparison of the efficacy and safety of 0.1% tacrolimus ointment with topical corticosteroids
users of topical tacrolimus, pimecrolimus, and corticosteroids (Joint European Longitudinal Lymphoma and Skin Cancer Evaluation (JOELLE)

1.0.2147/CLEP.S331287

Hashizume H, Yagi H, Ohshima A, Ito T, Horibe N, Yoshinari Y, Takigawa M:

Dermatol. 2002, 47:562-70.

Reitamo S, Ortonne JP, Sand C, et al.: Atopic dermatitis: results of a two-year, multicentre, non-comparative study

1.100118/j.id.13954

Benny AM, Laxmipriya S, Vezhavendhan N:

Pediatr. 2016, 16:75.

Siegfried EC, Jaworski JC, Kaiser JD, Hebert AA:

Cochrane Database Syst Rev. 2015, CD009864.

Laeijendecker R, Tank B, Dekker SK, Neumann HA:

Dermatol Ther. 2006, 19:118-26.

Ko HC, Kim WI, Cho SH, et al.: Topical tacrolimus for the treatment of atopic dermatitis in Japan

Clin Drug Invest. 2006, 26:235-46. 10.2165/00003495-200626050-00001

Ohtsuki M, Morimoto H, Nakagawa H: Tacrolimus ointment for the treatment of adult and pediatric atopic dermatitis: review on safety and benefits

J Dermatol. 2018, 45:996-42. 10.1111/1346-8138.14501

Mandelin J, Remitz A, Vrinten H, Reitamo S: One-year treatment with 0.1% tacrolimus ointment versus a corticosteroid regimen in adults with moderate to severe atopic dermatitis: a randomized, double-blind, comparative trial

Acta Derm Venereol. 2010, 90:170-4. 10.2340/00015555-0805

Axon E, Chalmers JR, Santer M, et al.: Safety of topical calcineurin inhibitors in atopic eczema: an umbrella review . BMJ Open. 2021, 11:e046476. 10.1136/bmjopen-2020-046476

Abéd N, Pawlichzki R: Efficacy and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis: meta-analysis of randomized clinical trials. Postepy Dermatol Alergor 2019, 56:752-9. 10.5114/ada.2019.91425

Koh K, Jun I, Kim TI, Kim EK, Seo KY: Long-term results of topical 0.02% tacrolimus ointment for refractory ocular surface inflammation in pediatric patients. BMC Ophthalmol. 2021, 21:247. 10.1186/s12886-021-01998-0

Calzavara-Pinton P, Fabbrocini G, Girolomoni G, et al.: Topical tacrolimus in adult atopic dermatitis: a consensus based on a 15-year experience. G Ital Dermatol Venereol. 2020, 155:8-8. 10.2376/s0039-0488.19.06478-2

Reitamo S, Rustin M, Ruźicka T, et al.: Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis. J Allergy Clin Immunol. 2002, 109:547-55. 10.1067/mai.2002.121832

Arkwright PD, Motala C, Subramanian H, Spergel J, Schneider LC, Wollenberg A: Management of difficult-to-treat atopic dermatitis. J Allergy Clin Immunol Pract. 2015, 1:142-51. 10.1016/j.jaccip.2012.09.002

Siegrfried EC, Jaworski JC, Kaiser JD, Hebert AA: Systematic review of published trials: Long-term safety of topical corticosteroids and topical calcineurin inhibitors in pediatric patients with atopic dermatitis. BMC Pediatr. 2016, 16:75. 10.1186/s12887-016-0607-9

Manjhi M, Yadav P, Mohan S, Sonthalia S, Ramesh V, Kashyap V: A comparative study of topical tacrolimus and topical triamcinolone acetonide in nodular scabies. Dermatol Ther. 2020, 33:e13954. 10.1111/dth.13954

Svensson A, Chambers C, Gáñemo A, Mitchell SA: A systematic review of tacrolimus ointment compared with corticosteroids in the treatment of atopic dermatitis. Curr Med Res Opin. 2011, 27:1395-406. 10.1185/00007995.2011.582483

Furue M, Takeuchi S: Topical tacrolimus as treatment of atopic dermatitis. Clin Cosmet Investig Dermatol. 2009, 2:161-6. 10.2147/cid.s4122

Furue M, Ushio H, Morei Y, Ogawa S, Nakahara T, Urabe K: Topical tacrolimus in the management of atopic dermatitis. Dermatol Ther. 2006, 19:118-26. 10.1111/j.1529-8019.2006.00064.x

Cury Martins J, Martins C, Aoki V, Gois AF, Ishii HA, da Silva EM: Topical tacrolimus for atopic dermatitis. Cochran eDatabase Syst Rev. 2015, CD009864. 10.1002/14651858.CD009864.pub2

Reitamo S, Ortonne JP, Sand C, et al.: A multicentre, randomized, double-blind, controlled study of long-term treatment with 0.1% tacrolimus ointment in adults with moderate to severe atopic dermatitis. Br J Dermatol. 2005, 152:1282-9. 10.1111/j.1365-2133.2005.06592.x

Ko HC, Kim WJ, Cho SH, et al.: Topical tacrolimus for the treatment of atopic dermatitis with truncal lesion. Ann Dermatol. 2018, 30:173-8. 10.5021/ad.2018.30.2.173

Laeijendecker R, Tank B, Dekker SK, Neumann HA: A comparison of treatment of oral lichen planus with topical tacrolimus and triamcinolone acetonide ointment. Acta Derm Venereol. 2006, 86:227-9. 10.2340/00015555-0070

Wang X, Zhang L, Luo J, et al.: Tacrolimus 0.03% ointment in labial discoid lupus erythematosus: a randomized, controlled clinical trial. J Clin Pharmacol. 2015, 55:1221-8. 10.1002/jcph.537

Williams HC: Clinical practice. Atopic dermatitis. N Engl J Med. 2005, 352:2514-24. 10.1056/NEJMep042803

Soter NA, Fleischer AB Jr, Webster GF, Monroe E, Lawrence I: Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part II, safety. J Am Acad Dermatol. 2001, 44:S9-46. 10.1016/j.jaad.2001.09.017

Reitamo S, Rissansen J, Remitz A, et al.: Tacrolimus ointment does not affect collagen synthesis: results of a single-center randomized trial. J Invest Dermatol. 1998, 111:396-8. 10.1046/j.1523-1747.1998.00323.x

Ohtsuki M, Morimoto H, Nakagawa H: Tacrolimus ointment for the treatment of atopic dermatitis is not associated with an increase in cutaneous infections. J Am Acad Dermatol. 2002, 47:562-70. 10.1016/s0190-9622(02)00347-7

Hashizume H, Yagi H, Ohshima A, Ito T, Horibe N, Yoshinari Y, Takigawa M: Comparable risk of herpes simplex virus infection between topical treatments with tacrolimus and corticosteroids in adults with atopic dermatitis. Br J Dermatol. 2006, 154:1204-6. 10.1111/j.1365-2133.2006.07245.x

Reitamo S, Ortonne JP, Sand C, et al.: Long-term treatment with 0.1% tacrolimus ointment in adults with atopic dermatitis: results of a two-year, multicentre, non-comparative study. Acta Derm Venereol. 2007, 87:406-12. 10.2340/00015555-0282

Arana A, Pottegård A, Kuiper JG, et al.: Long-term risk of skin cancer and lymphoma in users of topical tacrolimus and pimecrolimus: final results from the extension of the cohort study Protopic Joint European Longitudinal Lymphoma and Skin Cancer Evaluation (JOELLE). Clin Epidemiol. 2021, 13:1141-53. 10.2147/CLEP.S31287

Castellsague J, Kuiper JG, Pottegård A, et al.: A cohort study on the risk of lymphoma and skin cancer in users of topical tacrolimus, pimecrolimus, and corticosteroids (Joint European Longitudinal Lymphoma and Skin Cancer Evaluation)
Skin Cancer Evaluation - JOELLE study. Clin Epidemiol. 2018, 10:299-310. 10.2147/CLEP.S146442

112. Morita M, Asoda S, Tsunoda K, et al.: The onset risk of carcinoma in patients continuing tacrolimus topical treatment for oral lichen planus: a case report. Odontology. 2017, 105:262-6. 10.1007/s10266-016-0255-4

113. El-Batawy MM, Bossela MA, Mashaly HM, Hafez VS: Topical calcineurin inhibitors in atopic dermatitis: a systematic review and meta-analysis. J Dermatol Sci. 2009, 54:76-87. 10.1016/j.jdermsci.2009.02.002

114. Buys LM: Treatment options for atopic dermatitis. Am Fam Physician. 2007, 75:523-528.

115. Arellano FM, Wentworth CE, Arana A, Fernández C, Paul CF: Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis. J Invest Dermatol. 2007, 127:808-16. 10.1038/sj.jid.5700622

116. Siegfried EC, Jaworski JC, Hebert AA: Topical calcineurin inhibitors and lymphoma risk: evidence update with implications for daily practice. Am J Clin Dermatol. 2015, 14:165-73. 10.1007/s40257-015-0020-1

117. Paller AS, Fölster-Holst R, Chen SC, Diepgen TL, Elmets C, Margolis DJ, Pollock BH: No evidence of increased cancer incidence in children using topical tacrolimus for atopic dermatitis. J Am Acad Dermatol. 2020, 83:575-81. 10.1016/j.jaad.2020.03.075

118. Kapp A, Allen BR, Reitamo S: Atopic dermatitis management with tacrolimus ointment (Protopic®). J Dermatolog Treat. 2005, 14:5-16. 10.1080/095466654.2005.11864618

119. Cheer SM, Plosker GL: Tacrolimus ointment. A review of its therapeutic potential as a topical therapy in atopic dermatitis. J Am Acad Dermatol. 2001, 2:389-406. 10.2165/00128071-200102060-00005

120. Kikuchi K, Tagami H: Comparison of the effects of daily applications between topical corticosteroid and tacrolimus ointments on normal skin: evaluation with noninvasive methods. Dermatology. 2002, 205:578-82. 10.1159/000066432

121. Ruzicka T, Assmann T, Homey B: Tacrolimus: the drug for the turn of the millennium?. Arch Dermatol. 1999, 135:574-80. 10.1001/archderm.135.5.574